- Home
- IBRX vs CALX Comparison
IBRX vs CALX Comparison
Compare IBRX & CALX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBRX
- CALX
- Stock Information
- Founded
- IBRX 2014
- CALX 1999
- Country
- IBRX United States
- CALX United States
- Employees
- IBRX N/A
- CALX N/A
- Industry
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- CALX Telecommunications Equipment
- Sector
- IBRX Health Care
- CALX Consumer Discretionary
- Exchange
- IBRX Nasdaq
- CALX Nasdaq
- Market Cap
- IBRX 2.4B
- CALX 2.1B
- IPO Year
- IBRX N/A
- CALX 2010
- Fundamental
- Price
- IBRX $2.81
- CALX $36.07
- Analyst Decision
- IBRX Buy
- CALX Strong Buy
- Analyst Count
- IBRX 2
- CALX 6
- Target Price
- IBRX $17.38
- CALX $42.50
- AVG Volume (30 Days)
- IBRX 5.6M
- CALX 848.5K
- Earning Date
- IBRX 11-12-2024
- CALX 01-27-2025
- Dividend Yield
- IBRX N/A
- CALX N/A
- EPS Growth
- IBRX N/A
- CALX N/A
- EPS
- IBRX N/A
- CALX N/A
- Revenue
- IBRX $7,332,000.00
- CALX $890,128,000.00
- Revenue This Year
- IBRX $2,572.99
- CALX N/A
- Revenue Next Year
- IBRX $747.59
- CALX $3.13
- P/E Ratio
- IBRX N/A
- CALX N/A
- Revenue Growth
- IBRX 1218.71
- CALX N/A
- 52 Week Low
- IBRX $2.82
- CALX $26.76
- 52 Week High
- IBRX $10.53
- CALX $45.15
- Technical
- Relative Strength Index (RSI)
- IBRX 29.17
- CALX 59.14
- Support Level
- IBRX $2.82
- CALX $34.55
- Resistance Level
- IBRX $3.18
- CALX $36.55
- Average True Range (ATR)
- IBRX 0.28
- CALX 1.09
- MACD
- IBRX -0.23
- CALX 0.41
- Stochastic Oscillator
- IBRX 1.25
- CALX 89.12
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe.
About CALX Calix Inc
Calix Inc develops, market and sell Calix cloud, systems and software platforms to enable service providers of all types and sizes to innovate and transform. The company's customers utilize the real-time data and insights from Calix platforms to simplify their business and deliver experiences that excite their subscribers. The resulting growth in subscriber acquisition, loyalty and revenue creates more value for their businesses and communities. The Company's revenue is principally derived in the United States and it also has its presence in Middle East & Africa, Europe, Asia Pacific and other markets.